カテゴリ： 世界, 医療/バイオ, Market Monitor Global

二重抗体薬のグローバル市場展望 2023年-2029年：レモバブ、BLINCYTO、その他

■ 英語タイトル：Double Barreled Antibodies Drug Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23LY8480）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23LY8480
■ 発行日：2023年7月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医薬品＆ヘルスケア
■ ページ数：76
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[二重抗体薬のグローバル市場展望 2023年-2029年：レモバブ、BLINCYTO、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界の二重抗体薬市場規模と予測を収録しています。・世界の二重抗体薬市場：売上、2018年-2023年、2024年-2029年
・世界の二重抗体薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の二重抗体薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「レモバブ」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

二重抗体薬のグローバル主要企業は、Amgen Inc.、 F. Hoffman La Roche Ltd.、 AbbVie Inc.、 OncoMed Pharmaceuticals, Inc.、 Glenmark Pharmaceuticals Limited、 Xencor, Inc.、 MacroGenics, Inc.、 Aptevo Therapeutics Inc.、 Ligand Pharmaceuticals, Inc.、 Regeneron Pharmaceuticals, Inc.、 Fresenius SE & Co. KGaA、 Merus N.V.などです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、二重抗体薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の二重抗体薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の二重抗体薬市場：タイプ別市場シェア、2022年
・レモバブ、BLINCYTO、その他

世界の二重抗体薬市場：用途別、2018年-2023年、2024年-2029年
世界の二重抗体薬市場：用途別市場シェア、2022年
・肺がん、脳がん、肝臓がん、その他

世界の二重抗体薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の二重抗体薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における二重抗体薬のグローバル売上、2018年-2023年
・主要企業における二重抗体薬のグローバル売上シェア、2022年
・主要企業における二重抗体薬のグローバル販売量、2018年-2023年
・主要企業における二重抗体薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Amgen Inc.、 F. Hoffman La Roche Ltd.、 AbbVie Inc.、 OncoMed Pharmaceuticals, Inc.、 Glenmark Pharmaceuticals Limited、 Xencor, Inc.、 MacroGenics, Inc.、 Aptevo Therapeutics Inc.、 Ligand Pharmaceuticals, Inc.、 Regeneron Pharmaceuticals, Inc.、 Fresenius SE & Co. KGaA、 Merus N.V.

*************************************************************

・調査・分析レポートの概要
二重抗体薬市場の定義
市場セグメント
世界の二重抗体薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の二重抗体薬市場規模
世界の二重抗体薬市場規模：2022年 VS 2029年
世界の二重抗体薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの二重抗体薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の二重抗体薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：レモバブ、BLINCYTO、その他
二重抗体薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：肺がん、脳がん、肝臓がん、その他
二重抗体薬の用途別グローバル売上・予測

・地域別市場分析
地域別二重抗体薬市場規模 2022年と2029年
地域別二重抗体薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Amgen Inc.、 F. Hoffman La Roche Ltd.、 AbbVie Inc.、 OncoMed Pharmaceuticals, Inc.、 Glenmark Pharmaceuticals Limited、 Xencor, Inc.、 MacroGenics, Inc.、 Aptevo Therapeutics Inc.、 Ligand Pharmaceuticals, Inc.、 Regeneron Pharmaceuticals, Inc.、 Fresenius SE & Co. KGaA、 Merus N.V.
...

This report aims to provide a comprehensive presentation of the global market for Double Barreled Antibodies Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Double Barreled Antibodies Drug. This report contains market size and forecasts of Double Barreled Antibodies Drug in global, including the following market information:
Global Double Barreled Antibodies Drug Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Double Barreled Antibodies Drug Market Sales, 2018-2023, 2024-2029, (K Pcs)
Global top five Double Barreled Antibodies Drug companies in 2022 (%)
The global Double Barreled Antibodies Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Removab Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Double Barreled Antibodies Drug include Amgen Inc., F. Hoffman La Roche Ltd., AbbVie Inc., OncoMed Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Xencor, Inc., MacroGenics, Inc., Aptevo Therapeutics Inc. and Ligand Pharmaceuticals, Inc., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Double Barreled Antibodies Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Double Barreled Antibodies Drug Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Double Barreled Antibodies Drug Market Segment Percentages, by Type, 2022 (%)
Removab
BLINCYTO
Others
Global Double Barreled Antibodies Drug Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Double Barreled Antibodies Drug Market Segment Percentages, by Application, 2022 (%)
Lung Cancer
Brain Cancer
Liver Cancer
Others
Global Double Barreled Antibodies Drug Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Double Barreled Antibodies Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Double Barreled Antibodies Drug revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Double Barreled Antibodies Drug revenues share in global market, 2022 (%)
Key companies Double Barreled Antibodies Drug sales in global market, 2018-2023 (Estimated), (K Pcs)
Key companies Double Barreled Antibodies Drug sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Amgen Inc.
F. Hoffman La Roche Ltd.
AbbVie Inc.
OncoMed Pharmaceuticals, Inc.
Glenmark Pharmaceuticals Limited
Xencor, Inc.
MacroGenics, Inc.
Aptevo Therapeutics Inc.
Ligand Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Fresenius SE & Co. KGaA
Merus N.V.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Double Barreled Antibodies Drug, market overview.
Chapter 2: Global Double Barreled Antibodies Drug market size in revenue and volume.
Chapter 3: Detailed analysis of Double Barreled Antibodies Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Double Barreled Antibodies Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Double Barreled Antibodies Drug capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Double Barreled Antibodies Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Double Barreled Antibodies Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Double Barreled Antibodies Drug Overall Market Size
2.1 Global Double Barreled Antibodies Drug Market Size: 2022 VS 2029
2.2 Global Double Barreled Antibodies Drug Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Double Barreled Antibodies Drug Sales: 2018-2029
3 Company Landscape
3.1 Top Double Barreled Antibodies Drug Players in Global Market
3.2 Top Global Double Barreled Antibodies Drug Companies Ranked by Revenue
3.3 Global Double Barreled Antibodies Drug Revenue by Companies
3.4 Global Double Barreled Antibodies Drug Sales by Companies
3.5 Global Double Barreled Antibodies Drug Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Double Barreled Antibodies Drug Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Double Barreled Antibodies Drug Product Type
3.8 Tier 1, Tier 2 and Tier 3 Double Barreled Antibodies Drug Players in Global Market
3.8.1 List of Global Tier 1 Double Barreled Antibodies Drug Companies
3.8.2 List of Global Tier 2 and Tier 3 Double Barreled Antibodies Drug Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Double Barreled Antibodies Drug Market Size Markets, 2022 & 2029
4.1.2 Removab
4.1.3 BLINCYTO
4.1.4 Others
4.2 By Type – Global Double Barreled Antibodies Drug Revenue & Forecasts
4.2.1 By Type – Global Double Barreled Antibodies Drug Revenue, 2018-2023
4.2.2 By Type – Global Double Barreled Antibodies Drug Revenue, 2024-2029
4.2.3 By Type – Global Double Barreled Antibodies Drug Revenue Market Share, 2018-2029
4.3 By Type – Global Double Barreled Antibodies Drug Sales & Forecasts
4.3.1 By Type – Global Double Barreled Antibodies Drug Sales, 2018-2023
4.3.2 By Type – Global Double Barreled Antibodies Drug Sales, 2024-2029
4.3.3 By Type – Global Double Barreled Antibodies Drug Sales Market Share, 2018-2029
4.4 By Type – Global Double Barreled Antibodies Drug Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Double Barreled Antibodies Drug Market Size, 2022 & 2029
5.1.2 Lung Cancer
5.1.3 Brain Cancer
5.1.4 Liver Cancer
5.1.5 Others
5.2 By Application – Global Double Barreled Antibodies Drug Revenue & Forecasts
5.2.1 By Application – Global Double Barreled Antibodies Drug Revenue, 2018-2023
5.2.2 By Application – Global Double Barreled Antibodies Drug Revenue, 2024-2029
5.2.3 By Application – Global Double Barreled Antibodies Drug Revenue Market Share, 2018-2029
5.3 By Application – Global Double Barreled Antibodies Drug Sales & Forecasts
5.3.1 By Application – Global Double Barreled Antibodies Drug Sales, 2018-2023
5.3.2 By Application – Global Double Barreled Antibodies Drug Sales, 2024-2029
5.3.3 By Application – Global Double Barreled Antibodies Drug Sales Market Share, 2018-2029
5.4 By Application – Global Double Barreled Antibodies Drug Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Double Barreled Antibodies Drug Market Size, 2022 & 2029
6.2 By Region – Global Double Barreled Antibodies Drug Revenue & Forecasts
6.2.1 By Region – Global Double Barreled Antibodies Drug Revenue, 2018-2023
6.2.2 By Region – Global Double Barreled Antibodies Drug Revenue, 2024-2029
6.2.3 By Region – Global Double Barreled Antibodies Drug Revenue Market Share, 2018-2029
6.3 By Region – Global Double Barreled Antibodies Drug Sales & Forecasts
6.3.1 By Region – Global Double Barreled Antibodies Drug Sales, 2018-2023
6.3.2 By Region – Global Double Barreled Antibodies Drug Sales, 2024-2029
6.3.3 By Region – Global Double Barreled Antibodies Drug Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Double Barreled Antibodies Drug Revenue, 2018-2029
6.4.2 By Country – North America Double Barreled Antibodies Drug Sales, 2018-2029
6.4.3 US Double Barreled Antibodies Drug Market Size, 2018-2029
6.4.4 Canada Double Barreled Antibodies Drug Market Size, 2018-2029
6.4.5 Mexico Double Barreled Antibodies Drug Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Double Barreled Antibodies Drug Revenue, 2018-2029
6.5.2 By Country – Europe Double Barreled Antibodies Drug Sales, 2018-2029
6.5.3 Germany Double Barreled Antibodies Drug Market Size, 2018-2029
6.5.4 France Double Barreled Antibodies Drug Market Size, 2018-2029
6.5.5 U.K. Double Barreled Antibodies Drug Market Size, 2018-2029
6.5.6 Italy Double Barreled Antibodies Drug Market Size, 2018-2029
6.5.7 Russia Double Barreled Antibodies Drug Market Size, 2018-2029
6.5.8 Nordic Countries Double Barreled Antibodies Drug Market Size, 2018-2029
6.5.9 Benelux Double Barreled Antibodies Drug Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Double Barreled Antibodies Drug Revenue, 2018-2029
6.6.2 By Region – Asia Double Barreled Antibodies Drug Sales, 2018-2029
6.6.3 China Double Barreled Antibodies Drug Market Size, 2018-2029
6.6.4 Japan Double Barreled Antibodies Drug Market Size, 2018-2029
6.6.5 South Korea Double Barreled Antibodies Drug Market Size, 2018-2029
6.6.6 Southeast Asia Double Barreled Antibodies Drug Market Size, 2018-2029
6.6.7 India Double Barreled Antibodies Drug Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Double Barreled Antibodies Drug Revenue, 2018-2029
6.7.2 By Country – South America Double Barreled Antibodies Drug Sales, 2018-2029
6.7.3 Brazil Double Barreled Antibodies Drug Market Size, 2018-2029
6.7.4 Argentina Double Barreled Antibodies Drug Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Double Barreled Antibodies Drug Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Double Barreled Antibodies Drug Sales, 2018-2029
6.8.3 Turkey Double Barreled Antibodies Drug Market Size, 2018-2029
6.8.4 Israel Double Barreled Antibodies Drug Market Size, 2018-2029
6.8.5 Saudi Arabia Double Barreled Antibodies Drug Market Size, 2018-2029
6.8.6 UAE Double Barreled Antibodies Drug Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Amgen Inc.
7.1.1 Amgen Inc. Company Summary
7.1.2 Amgen Inc. Business Overview
7.1.3 Amgen Inc. Double Barreled Antibodies Drug Major Product Offerings
7.1.4 Amgen Inc. Double Barreled Antibodies Drug Sales and Revenue in Global (2018-2023)
7.1.5 Amgen Inc. Key News & Latest Developments
7.2 F. Hoffman La Roche Ltd.
7.2.1 F. Hoffman La Roche Ltd. Company Summary
7.2.2 F. Hoffman La Roche Ltd. Business Overview
7.2.3 F. Hoffman La Roche Ltd. Double Barreled Antibodies Drug Major Product Offerings
7.2.4 F. Hoffman La Roche Ltd. Double Barreled Antibodies Drug Sales and Revenue in Global (2018-2023)
7.2.5 F. Hoffman La Roche Ltd. Key News & Latest Developments
7.3 AbbVie Inc.
7.3.1 AbbVie Inc. Company Summary
7.3.2 AbbVie Inc. Business Overview
7.3.3 AbbVie Inc. Double Barreled Antibodies Drug Major Product Offerings
7.3.4 AbbVie Inc. Double Barreled Antibodies Drug Sales and Revenue in Global (2018-2023)
7.3.5 AbbVie Inc. Key News & Latest Developments
7.4 OncoMed Pharmaceuticals, Inc.
7.4.1 OncoMed Pharmaceuticals, Inc. Company Summary
7.4.2 OncoMed Pharmaceuticals, Inc. Business Overview
7.4.3 OncoMed Pharmaceuticals, Inc. Double Barreled Antibodies Drug Major Product Offerings
7.4.4 OncoMed Pharmaceuticals, Inc. Double Barreled Antibodies Drug Sales and Revenue in Global (2018-2023)
7.4.5 OncoMed Pharmaceuticals, Inc. Key News & Latest Developments
7.5 Glenmark Pharmaceuticals Limited
7.5.1 Glenmark Pharmaceuticals Limited Company Summary
7.5.2 Glenmark Pharmaceuticals Limited Business Overview
7.5.3 Glenmark Pharmaceuticals Limited Double Barreled Antibodies Drug Major Product Offerings
7.5.4 Glenmark Pharmaceuticals Limited Double Barreled Antibodies Drug Sales and Revenue in Global (2018-2023)
7.5.5 Glenmark Pharmaceuticals Limited Key News & Latest Developments
7.6 Xencor, Inc.
7.6.1 Xencor, Inc. Company Summary
7.6.2 Xencor, Inc. Business Overview
7.6.3 Xencor, Inc. Double Barreled Antibodies Drug Major Product Offerings
7.6.4 Xencor, Inc. Double Barreled Antibodies Drug Sales and Revenue in Global (2018-2023)
7.6.5 Xencor, Inc. Key News & Latest Developments
7.7 MacroGenics, Inc.
7.7.1 MacroGenics, Inc. Company Summary
7.7.2 MacroGenics, Inc. Business Overview
7.7.3 MacroGenics, Inc. Double Barreled Antibodies Drug Major Product Offerings
7.7.4 MacroGenics, Inc. Double Barreled Antibodies Drug Sales and Revenue in Global (2018-2023)
7.7.5 MacroGenics, Inc. Key News & Latest Developments
7.8 Aptevo Therapeutics Inc.
7.8.1 Aptevo Therapeutics Inc. Company Summary
7.8.2 Aptevo Therapeutics Inc. Business Overview
7.8.3 Aptevo Therapeutics Inc. Double Barreled Antibodies Drug Major Product Offerings
7.8.4 Aptevo Therapeutics Inc. Double Barreled Antibodies Drug Sales and Revenue in Global (2018-2023)
7.8.5 Aptevo Therapeutics Inc. Key News & Latest Developments
7.9 Ligand Pharmaceuticals, Inc.
7.9.1 Ligand Pharmaceuticals, Inc. Company Summary
7.9.2 Ligand Pharmaceuticals, Inc. Business Overview
7.9.3 Ligand Pharmaceuticals, Inc. Double Barreled Antibodies Drug Major Product Offerings
7.9.4 Ligand Pharmaceuticals, Inc. Double Barreled Antibodies Drug Sales and Revenue in Global (2018-2023)
7.9.5 Ligand Pharmaceuticals, Inc. Key News & Latest Developments
7.10 Regeneron Pharmaceuticals, Inc.
7.10.1 Regeneron Pharmaceuticals, Inc. Company Summary
7.10.2 Regeneron Pharmaceuticals, Inc. Business Overview
7.10.3 Regeneron Pharmaceuticals, Inc. Double Barreled Antibodies Drug Major Product Offerings
7.10.4 Regeneron Pharmaceuticals, Inc. Double Barreled Antibodies Drug Sales and Revenue in Global (2018-2023)
7.10.5 Regeneron Pharmaceuticals, Inc. Key News & Latest Developments
7.11 Fresenius SE & Co. KGaA
7.11.1 Fresenius SE & Co. KGaA Company Summary
7.11.2 Fresenius SE & Co. KGaA Double Barreled Antibodies Drug Business Overview
7.11.3 Fresenius SE & Co. KGaA Double Barreled Antibodies Drug Major Product Offerings
7.11.4 Fresenius SE & Co. KGaA Double Barreled Antibodies Drug Sales and Revenue in Global (2018-2023)
7.11.5 Fresenius SE & Co. KGaA Key News & Latest Developments
7.12 Merus N.V.
7.12.1 Merus N.V. Company Summary
7.12.2 Merus N.V. Double Barreled Antibodies Drug Business Overview
7.12.3 Merus N.V. Double Barreled Antibodies Drug Major Product Offerings
7.12.4 Merus N.V. Double Barreled Antibodies Drug Sales and Revenue in Global (2018-2023)
7.12.5 Merus N.V. Key News & Latest Developments
8 Global Double Barreled Antibodies Drug Production Capacity, Analysis
8.1 Global Double Barreled Antibodies Drug Production Capacity, 2018-2029
8.2 Double Barreled Antibodies Drug Production Capacity of Key Manufacturers in Global Market
8.3 Global Double Barreled Antibodies Drug Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Double Barreled Antibodies Drug Supply Chain Analysis
10.1 Double Barreled Antibodies Drug Industry Value Chain
10.2 Double Barreled Antibodies Drug Upstream Market
10.3 Double Barreled Antibodies Drug Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Double Barreled Antibodies Drug Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 高シュウ酸尿症一次治療薬のグローバル市場展望 2023年-2029年：ALLN-230、DCR-PHXC、ALN-GO1、その他
  • I型高リポタンパク血症治療薬のグローバル市場展望 2023年-2029年：アリポジーンティパルボベク、CAT-2003、ISIS-APOCIIIRx、メシル酸ロミタピド、プラディガスタットナトリウム、その他
  • 運動促進薬のグローバル市場展望 2023年-2029年：メトクロプラミド、ドンペリドン、シサプリド、その他
  • 慢性疲労症候群治療薬のグローバル市場展望 2023年-2029年：鎮痛剤・NSAID、抗うつ薬・抗精神病薬、抗菌薬・免疫調節薬
  • 発作性夜間ヘモグロビン尿症治用療薬のグローバル市場展望 2023年-2029年：エクリズマブ、ラブリズマブ、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23LY8480 )"二重抗体薬のグローバル市場展望 2023年-2029年：レモバブ、BLINCYTO、その他" (英文：Double Barreled Antibodies Drug Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。